Introduction {#S0001}
============

Interferon α-2b (IFNα-2b) is a type of cytokine protein with broad-spectrum antitumor[@CIT0001], antiviral,[@CIT0002] and immune enhancement[@CIT0003] activities. It is one of the most important antitumor biological products in clinical practice today. Recombinant human interferon α-2b (rhIFNα-2b) has the same biological activity as natural human IFNα-2b, which is combined with other drugs to treat small cell or non-small cell lung cancers continuously.[@CIT0004] Like most protein drugs, the half-life of rhIFNɑ-2b is short,[@CIT0005] drug utilization rate is low, and the preparation process and releasing environment significantly influence its stability.[@CIT0006] In brief, the above shortcomings limit it for wider applications. Therefore, a new formulation of this cytokine is desired to improve its encapsulation and sustained release.

The ion-exchange technique has been widely used in many areas, such as ionic chemical drug delivery systems, protein purification, suspension formulations, etc.[@CIT0007],[@CIT0008] It has also been applied in protein polypeptide drug delivery systems. Compared to the crude drug, the drug--resin composite improves the stability and retention rate of enzyme activity. Traditional ion-exchange resins[@CIT0009] (Amberlite GC120 and Amberlite IRP69) are based on polystyrene diethylbenzene, which is nonbiodegradable and difficult to use in the study of protein drug delivery systems for injection. In addition, the protein drug has a molecular weight between 10 and 1000 kDa, so it is difficult to enter the smooth and dense interior of ion-exchange resins in large quantities, resulting in low drug loading. Nanoporous microspheres are suitable for embedding and controlling the release of rhIFNα-2b at a molecular weight of 19 kDa.[@CIT0010]

In order to solve the above problems, carboxymethyl chitosan (CC) is proposed in this study as the carrier for ion exchange. CC is a chitosan derivative, and CC is a type of amphoteric polymer with good water solubility, biocompatibility, biodegradability, low toxicity, and pH responsiveness. In recent years, CC has been widely used in biomedical,[@CIT0011]--[@CIT0013] tissue engineering,[@CIT0014],[@CIT0015] wound dressing,[@CIT0016] agricultural film, and other health care products. In particular, it has become a new favorite in the field of pharmaceutical research. CC can be prepared into hydrogels,[@CIT0017]--[@CIT0019] drug conjugates,[@CIT0020] biodegradable sustained-release carriers, polyelectrolyte complexes,[@CIT0021] etc. In addition, CC can also be used for the delivery of anticancer drugs,[@CIT0022] antibacterial drugs,[@CIT0023] anti-inflammatory drugs,[@CIT0024] and genes.[@CIT0025] Its application in the field of protein polypeptide drug delivery systems has received increasing attention.[@CIT0026]

In this article, CC sodium was used as a carrier material to prepare nanoporous microspheres. CC has good biocompatibility and biodegradability[@CIT0027] and is a safe sustained-release carrier. Once crosslinked, carboxymethyl chitosan nano-porous microspheres (CCPM) is insoluble in water, has a certain spatial three-dimensional structure, and retains its carboxyl group for ion exchange. Its carboxyl group is a weak acidic and ionizable group, which can bind the protein drug due to opposite electric charges. In this article, low-toxic ethyl acetate was used as a pore-forming agent to form a nanoporous microsphere. After preparing the blank nanoporous microspheres here, a dynamic drug-loading method was adopted. A dynamic drug-loading method could result in continuous drug concentration in the effluent, which could realize 100% drug loading and greatly reduce the loss of expensive drugs. The mechanism of that CCPM loading and release by ion exchange is shown in [Figure 1](#F0001){ref-type="fig"}. When the pH in vitro is less than the rhIFNα-2b isoelectric point, the rhIFNα-2b is positively charged, which can bind CC microsphere ions with negative electricity. The dynamic drug-loading process was stopped immediately when the drug was detected in the effluent, and the drug utilization rate in theory can reach 100%. In the physiological environment of the human body, the positive ions (such as Na^+^) in the body can release the rhIFNα-2b transposition on the nanoporous microsphere, where the drug plays its biological role.Figure 1The mechanism of CCPM loading and releasing drugs by ion exchange.**Abbreviation:** CCPM, carboxymethyl chitosan nanoporous microspheres.

To an extent, the dynamic drug-loading method can solve problems of low encapsulation rate of microspheres and loss of drug activity during drug loading. However, based on existing research,[@CIT0028] we know that ion exchange has a certain slow-release effect, but it is not enough. Therefore, this article adopted an electrostatic self-assembly technique to seal/cover the pores on the surface of the nanoporous microspheres to achieve a further slow-release effect.[@CIT0029] The electrostatic self-assembly technique mainly relies on electrostatic interactions between the assembled molecules to deposit polyelectrolytes alternately on the surface of the substrate and spontaneously form self-assembled films with special structures and functions.[@CIT0030],[@CIT0031] According to the literature,[@CIT0032] the self-assembly of polyelectrolyte layers outside the drug surface can delay the drug-release rate. Therefore, it is feasible that chitosan, with a positive charge, can be used to form a water-insoluble polyelectrolyte complex film on the surface of negatively charged drug-carrying nanoporous microspheres through electrostatic action to achieve slow release.

In general, in this article, a nanoporous ion-responsive targeted drug delivery system (PIRTDDS) was designed to improve drug availability of rhIFNα-2b and target the drug to the lung passively and with sustained release. The drug-loaded nanoporous microspheres were characterized by scanning electron microscopy (SEM), SDS-PAGE, and circular dichrogram (CD). In addition, the drug-release behavior in vitro, anti-lung cancer activity in vitro, pharmacokinetics in vivo, and tissue distribution of the drug-loaded nanoporous microspheres were also evaluated.

Materials {#S0002}
=========

rhIFNα-2b was obtained from Genid Biotechnology Co., Ltd. (Guizhou, China). CC was obtained from Bomei Biotechnology Co., Ltd. (Hefei, China). Coomassie Brilliant Blue G250 and R250 were both purchased from Sinopharm Chemical Reagent Co., Ltd. (Beijing, China). DMEM and thiazolyl blue tetrazolium bromide (MTT) were purchased from Gibco Company (Langley, OK, USA). FBS was purchased from Yuan Ye Biotechnology Co., Ltd. (Shanghai, China). Dimethyl sulfoxide (DMSO) was purchased from Sigma (Shanghai, China). A human lung adenocarcinoma cell line A549 was provided by the Institute of Life Sciences, Jiangsu University, and the use of the cell line was approved by the Ethics Committee of Jiangsu University. rhIFNɑ-2b kit was purchased from Crystal Biological Technique Co., Ltd. (Shanghai, China). CCPM was self-made. All the chemical reagents were obtained from Sinopharm Chemical Reagent Co., Ltd.. Lewis lung carcinoma cells were provided by Shanghai Zibo Biotechnology Co., Ltd.

Animals {#S0002-S2001}
-------

Clean Kunming mice (male, 18--24 g) and ICR mice (male, 20--25 g) were obtained from the Experimental Animal Center at Jiangsu University (Zhenjiang, Jiangsu, China). All animal experiments were carried out in accordance with the Guide for Care and Use of Laboratory Animals as adopted and promulgated by the Animal Ethics Committee of Jiangsu University. The experiments were approved by the Animal Ethics Committee of Jiangsu University.

Methods {#S0003}
=======

Preparation of blank CCPM {#S0003-S2001}
-------------------------

The blank CCPM was prepared following a previously reported method:[@CIT0033] 2 mL of ethyl acetate was used as a pore-forming agent, and 0.1 g CC was dissolved in 5 mL of normal saline at room temperature as the aqueous phase, and then emulsified with 0.1 g tween 80 for 30 mins. The emulsion was poured into polyvinyl alcohol (PVA) (10 mL, 1%, w/v) and again vortexed for 1 min before being placed into 40 mL of liquid paraffin with 0.8 g of span 80. The mixture was stirred at 900 rpm for 1 hr at room temperature. After 1 hr of emulsification, 0.16 mL of a 12.5% glutaraldehyde solution was slowly added at a constant speed. The solution was stirred and solidified for 3 hrs. Then, the nanoporous microspheres were washed by *n*-hexane three times to make a surface without a floating oil spot, dispersed with anhydrous ethanol, washed with deionized water, and obtained via centrifugation and freeze drying.

Fabrication of rhIFNα-2b-CCPM by ion exchange {#S0003-S2002}
---------------------------------------------

The loading process is shown in [Figure 2](#F0002){ref-type="fig"}. 450 mg of self-made nanoporous microspheres was soaked with deionized water for 30 mins, then the nanoporous microspheres were packed into a dynamic glass exchange column (Ф 16 mm x 20 cm). 0.75 mg/mL of a rhIFNa-2b solution (0.02 mol/L pH4.6 HAc--NaAc buffer solution) flowed through the column by 0.2 mL/min at 25±0.5°°C for about 44 mins, then deionized water was used to wash the surface of the nanoporous microspheres to remove unbound drugs. The Bradford method was used to determine the total outflow of drugs and to calculate the theoretical drug loading. Last, rhIFNα-2b-CCPM was obtained by freeze-drying.Figure 2The diagram of the dynamic loading drug process.**Abbreviation:** CCPM, carboxymethyl chitosan nanoporous microspheres.

Fabrication of CS-rhIFNα-2b-CCPM by self-assembly {#S0003-S2003}
-------------------------------------------------

5.4 g sodium acetate trihydrate was added to 50 mL of deionized water to prepare 1 mg/mL of a chitosan solution (HAc adjusted to pH 4.6) with ultrasonic treatment for 30 mins ([Figure 3](#F0003){ref-type="fig"}). After adding 37.5 mg of wet rhIFNα-2b-CCPM at 25°C, the self-assembly process occurred with magnetic stirring at 100 rpm for 15 mins. After centrifugal depuration, deionized water was added and washed 3 times to freeze and dry the composite nanoporous microsphere.Figure 3Schematic diagram of the electrostatic self-assembly technique.**Abbreviations:** rhIFNα-2b-CCPM, rhIFNα-2b carboxymethyl chitosan nanoporous microspheres; CS-rhIFNα-2b-CCPM, chitosan rhIFNα-2b carboxymethyl chitosan nanoporous microspheres.

Characterization {#S0004}
================

Morphology and particle size distribution of the nanoporous microspheres {#S0004-S2001}
------------------------------------------------------------------------

The morphological characteristics of CCPM, rhIFNα-2b-CCPM, and CS-rhIFNα-2b-CCPM were determined by SEM (S-4800, Hitachi, Tokyo, Japan). The size of CS-rhIFNα-2b-CCPM was measured by a laser scattering particle size analyzer (LS230, Beckman Coulter, Pasadena, CA, USA).

Drug content determination {#S0004-S2002}
--------------------------

25 mg of CS-rhIFNα-2b-CCPM was accurately weighed and added to 2.5 mL of a 1 mol/L HCl solution and sonicated for 1 hr in an ice bath, and then shaken at 50 rpm at 37±0.5°C for 24 hrs. 2.5 mL of 1 mol/L NaOH was added for neutralization. Then, the sample was centrifuged at 10,000 rpm for 5 mins at 4°C. The supernatant was collected and the absorbance was determined by using the Bradford method to calculate the content of rhIFNα-2b. Three parallel tests on each sample were performed, and the actual encapsulation rate (*r*E) and drug-loading rate (*r*DL) of the nanoporous microsphere was calculated as indicated in [Equations 1](#M0001) and [2](#M0002). $$\documentclass[12pt]{minimal}
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where *m* is the content of protein mass in the nanoporous microsphere (mg) and *M* is the content of the nanoporous microsphere mass (mg). The *rDL* is the actual loading amount (μg/mg), *tDL* is the theoretical loading amount (μg/mg), and *rE* is the actual sealing rate.

In vitro release study {#S0004-S2003}
----------------------

A phosphate buffer solution[@CIT0034] (20 mmol/L, 5 mL, pH 7.4), containing 0.02% Tween 80, was added into a 5 mL tube, and then CS-rhIFNα-2b-CCPM (25 mg) was added into the tube and suspended thoroughly. The tube was placed in a 37±0.5°C water bath and shaken at 50 rpm horizontally. After 0.25, 0.5, 1, 2, 3, 4, 6, 12, 16, 24, and 30 hrs, samples were taken out and centrifuged at 10,000 rpm for 5 mins at 4°C. Three replicate tests were performed for the in vitro drug-release studies. The content of rhIFNα-2b was measured by the Bradford method. The cumulated released percent in vitro (*Q*) of the nanoporous microspheres was calculated as indicated in [Equation 3](#M0003): $$\documentclass[12pt]{minimal}
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where *C~t~* is the concentration of drug in the medium at the *t* sampling point, *W* is the total weight of the nanoporous microspheres in the medium (mg), *V*~0~ is the volume of the released medium (mL), *V* is the volume of each sampling (mL), and *X* is the amount of drug carried by the nanoporous microsphere (μg/mg).

To determine the drug-release profile, a zero-order release equation ([Equation 4](#M0004)), a first-order release equation ([Equation 5](#M0005)), the Higuchi equation ([Equation 6](#M0006)), and the Hixson and Crowell ([Equation 7](#M0007)) and Viswanathan ([Equation 8](#M0008)) equations were selected for fitting. $$\documentclass[12pt]{minimal}
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SDS-PAGE {#S0004-S2004}
--------

30 μL of different rhIFNα-2b sample solutions, 30 μL of the marker solution plus 10 μL of 4 × SDS gels, and sample buffer were blended and then heated for 10 mins using a 100°C water bath for protein denaturation. The concentration of resolving gel was 12% and stacking gel was 5%. Coomassie brilliant blue R250 was dyed and decolorized.

CD {#S0004-S2005}
--

The rhIFNα-2b-CCPM releasing solution was characterized by a CD and compared with the standard CD of rhIFNα-2b reported in the literature[@CIT0035] to observe the changes of its secondary structure. Test conditions were as follows: the xenon lamp (150 W), room temperature, ultraviolet scanning range area (195\~250 nm), the bandwidth of 1 nm, standard sensitivity, response time of 1 s, the scanning speed of 50 nm/min, the data step of 0.5 nm, and an optical path of 1 mm.

Relative biological activity in vitro {#S0004-S2006}
-------------------------------------

Lung adenocarcinoma A549 cells were cultured in DMEM containing 10% FBS and 1% penicillin and streptomycin at 37°C in a humidified atmosphere of 5% CO~2~.[@CIT0036],[@CIT0037] When the cells entered the logarithmic growth stage, they were seeded into 96-well plates (4x10^3^ cells per well) and cultured in a 200 μL cell suspension. The cells were treated with different concentrations of the rhIFNα-2b stock solution and the rhIFNα-2b-CCPM releasing solution (5, 10, 25, 40, and 50 μg/mL),[@CIT0038] then diluted with DMEM after 24 hrs of incubation. Cell culture medium was added to a negative control group. 96-well plates were incubated in 5% CO~2~ at 37°C for 72 hrs.

10 μL of the MTT solution[@CIT0039] (5 mg/mL) was added to each well and incubated for 4 hrs. After discarding the cell supernatant and adding 100 μL of DMSO into each well, the 96-well plate was shaken for 10 mins until the purple formazan crystals were solubilized. The OD values of each well were measured with a microplate reader at 490 nm. The cell inhibition rate (IR) from the 24-hr releasing solution was calculated as indicated in [Equation 9](#M0009) and the IR--concentration curve was drawn. Each experiment was repeated three times. The IC50 values were determined using a sigmoidal equilibrium model regression using XLfit version 4.3.2 (ID Business Solutions Ltd., Guildford, Surrey, UK) and are defined as the concentration of rhIFNα-2b required for a 50% reduction in growth/viability: $$\documentclass[12pt]{minimal}
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where *OD~c~* is the absorbance of the control group, *OD~t~* is the absorbance of the experimental group, and *OD*~0~ is the absorbance of the blank hole.

In vivo analytical methodology {#S0004-S2007}
------------------------------

Analysis methods were validated according to the established international guidelines and requirements (Validation of Analytical Methods: Definitions and Terminology, ICH Topic Q2A, and Validation of Analytical Procedure: Methodology, ICH Topic Q2B). Accuracy of the method was assessed on the basis of the coefficient of variation in quality control samples. Three standard kits were used to establish standard curves, and the coefficient of variation between the plates was calculated. For the recovery of plasma and tissue samples, 7.5, 30, and 120 pg/mL of rhIFNα-2b was added to each plasma and tissue homogenate supernatants, respectively. The extraction recovery was calculated with the standard curve.

In vivo pharmacokinetics and tissue distribution study {#S0004-S2008}
------------------------------------------------------

Eighty Kunming mice[@CIT0040] were randomly divided into three groups: 30 mice in the control group, 45 mice in the experimental group, and 5 mice in the blank group. All of the mice were fasted for 12 hrs before experiments, with free access to water. Before the pharmacokinetic study, the mice were anesthetized with pentobarbital sodium anesthesia (40 mg/kg).

For the control group, the tail vein was administered at 4.645 μg/kg rhIFNα-2b. 200 μL blood samples were withdrawn from the ocular veniplex[@CIT0041]--[@CIT0043] and placed in heparinized tubes at predetermined time intervals. Then, the mice were sacrificed, and the tissues were collected.

For the experimental group, 1.5 mg rhIFNα-2b-CCPM was accurately weighed (containing 18.75 μg rhIFNα-2b) and suspended in 20 mL of sterilized water containing 0.02% Tween 80. The sample was injected into the tail vein by 0.005 mL/g. 200 μL blood samples were withdrawn from ocular veniplex and placed in heparinized tubes at predetermined time intervals. Then, the mice were sacrificed, and the tissues were collected. Plasma samples were obtained by centrifugation at 4,000 rpm at 4°C for 15 mins, and then stored in an --80°C refrigerator for analysis.

The procedure followed the NHGRI Animal Care And Use Committee (ACUC) Guideline And Procedures For Retro-orbital.

For the tissue sample pretreatment, the tissue was flushed with PBS (0.01M pH 7.4) to remove residual blood, weighed and cut. Nine times the volume of PBS was mixed with the cut tissue in a homogenizer, fully ground and homogenized by further ultrasonic crushing. Finally, the homogenate was centrifugated at 10,000 rpm for 5\~10 mins, and the supernatant was collected and stored at −80°C for measurements. RhIFNα-2b concentrations in the plasma and tissues of mice were determined by the ELISA method.[@CIT0044]

The noncompartment model parameters of the plasma concentration--time curves of the stock solution and nanoporous microspheres were calculated by DAS 2.0 software. Taking the injection as a reference, the relative bioavailability of the drug-loaded nanoporous microspheres was calculated. The formula was as follows: $$\documentclass[12pt]{minimal}
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$$F = {{AU{C_T}} \over {AU{C_R}}} \times 100\% $$
\end{document}$$

*AUC~T~* is the bioavailability for the drug-loaded nanoporous microspheres and *AUC~R~* is the bioavailability of the injection solution.

Pharmacodynamic evaluation {#S0004-S2009}
--------------------------

The Lewis cells were rapidly placed in a 37°C water bath to resuscitate, then the cells were cultured in the culture medium in an incubator. When the Lewis cells were grown to logarithmic growth phase and the number of viable cells was greater than 95%, the cells were suspended in PBS to form a 1×10^7^ Lewis cell suspension. The suspension was injected into the subcutaneous of the left forelimb, and each mouse was injected with a 0.2 mL suspension. The tumor growth status of each mouse was observed, and the successfully modeled mice were selected for subsequent experiments.

Thirty-six successfully modeled ICR mice (20--25 g) were randomly divided into three groups: a control group (2 mg/kg, NS), a stock solution group (2 mg/kg, rhIFNα-2b), and a microsphere group (20 mg/kg, CS-rhIFNα-2b-CCPM), administered by the tail vein every day for 15 days.[@CIT0045]

The mice weight and tumor volume were measured every other day, and the volume of the tumor was calculated by [Equation 11](#M0011). After the last measurement, all mice were sacrificed, and the tumors were excised, weighed, and photographed. The dissected tumors and major organs, including the heart, liver, spleen, lungs, and kidneys, were gathered and then fixed in a 4% (w/v) paraformaldehyde solution for the following histological examinations that involved H&E staining, which were performed for the evaluation of antitumor effects. The tumor IR was calculated according to the following [Equation 12](#M0012). $$\documentclass[12pt]{minimal}
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where *a* is the tumor long diameter (mm) and *b* is the tumor width (mm). $$\documentclass[12pt]{minimal}
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In the formula, *Wc* is the tumor weight (g) of the control group and *Wt* is the tumor of the administered group (g).

Statistical analysis {#S0004-S2010}
--------------------

Data were obtained at least in triplicate and expressed as the mean±SD. A *t*-test (one-sample *t*-test) was conducted using SPSS statistical software, and the significance was evaluated based on *P*\<0.05.

Results and discussion {#S0005}
======================

Kinetics of drug loading {#S0005-S2001}
------------------------

As can be seen from [Figure 4](#F0004){ref-type="fig"}, in the initial stage of dynamic drug loading, the ion-exchange reaction between rhIFNα-2b and the nanoporous microspheres was sufficient, and rhIFNα-2b was rapidly bound to the site on the surface of the nanoporous microspheres. At this time, interferon was not detected in the effluent, and all rhIFNα-2b was loaded into the nanoporous microsphere resin, and the drug utilization rate was 100%. After about 44 mins, the nanoporous microsphere column gradually penetrated, the permeability rapidly increased to 0.1, and the permeability rapidly increased with time, but the drug utilization rate decreased rapidly accordingly. Considering the high price of protein drugs and their drug utilization rate, 44 mins was chosen as the time point to stop drug loading in this study.Figure 4The effect of time on permeability and drug utilization rate of the drug-loading process (n=3).

Characterization {#S0006}
================

Morphology and particle size distribution of the nanoporous microspheres {#S0006-S2001}
------------------------------------------------------------------------

As can be seen from [Figure 5Ai](#F0005){ref-type="fig"}, the microspheres had a uniform particle size distribution and optimal roundness. [Figure 5Aii](#F0005){ref-type="fig"} shows that the microspheres had obvious nanoporous structures of around 300--400 nm in diameter. [Figure 5Aiii](#F0005){ref-type="fig"} illustrates that there were still pores remaining on the surface of the nanoporous microspheres after drug loading. [Figure 5Aiv](#F0005){ref-type="fig"} shows that the pores on the surface of the nanoporous microspheres were covered, indicating that chitosan was successfully assembled on the surface of the nanoporous microspheres. It is known from the literature[@CIT0046] that the optimal size range required to achieve transient but efficient targeting of pulmonary capillaries after intravenous injection is between 6～10 μm in rats. Particles larger than 25 μm (larger than capillaries) can enter the venous circulation relatively unimpeded via the arteriovenous shunt of the lungs. As shown in [Figure 5B](#F0005){ref-type="fig"}, the CS-rhIFNα-2b-CCPM had a uniform distribution of particle sizes between 5 and 15 μm, with an average value of 9.46 μm, suggesting good lung-targeting efficiency.Figure 5Characterization studies. (**A**) SEM images (ⅰ: CCPM; ⅱ: surface of CCPM; ⅲ: rhIFNα-2b-CCPM; ⅳ: CS-rhIFNα-2b-CCPM); (**B**) Particle size distribution of CS-rhIFNα-2b-CCPM; (**C**) Accumulative release from the optimal formulation; (**D**) Electrophoretogram of different rhIFNα-2b samples dyed by Coomassie brilliant blue (a: rhIFNα-2b solution; b: rhIFNα-2b extracted from nanoporous microspheres; c: rhIFNα-2b release solution for 12 hrs; d: rhIFNα-2b extracted from nanoporous microspheres after in vitro release for 24 hrs; e: rhIFNα-2b in effluent and washing liquid); (**E**) Circular dichroism spectra of rhIFNα-2b; (**F**) Inhibition rate of cell proliferation (n=3); and (**G**) Micrograph of the inhibition effect of the nanoporous microsphere releasing solution with different concentrations on A549 cells.**Abbreviations:** CCPM, nanoporous microspheres; rhIFNα-2b-CCPM, rhIFNα-2b carboxymethyl chitosan nanoporous microspheres; CS-rhIFNα-2b-CCPM, chitosan rhIFNα-2b carboxymethyl chitosan nanoporous microspheres; IR, inhibition rate. 

Encapsulation efficiency and drug loading {#S0006-S2002}
-----------------------------------------

In recent years, much research has been attempted to improve encapsulation efficiency and drug loading. For example, Chen et al[@CIT0047] improved Shirasu porous glass (SPG) membrane emulsification based on traditional preparation methods for protein-loaded composite PLGA microspheres. The drug loading of the composite microspheres can be increased by 8%, and the encapsulation efficiency can be increased by 75.16%. In addition, Varma et al[@CIT0048] prepared chitosan microspheres. The entrapment efficiency of the drug loaded by a passive adsorption method was only 46%. As can be seen from [Table 1](#T0001){ref-type="table"}, the encapsulation efficiency of the nanoporous microspheres significantly increased to 89.91±0.38%, and the actual drug loading was 10.77±2.59%. This was due to the dynamic exchange process where the fresh drug solution underwent an ion-exchange reaction while continuously passing through the resin layer. The dynamic exchange process can effectively separate the exchanged solution from the resin with time and allow for the adequate solution exchange in the whole resin layer. In addition, the nanopores facilitated protein drug penetration and increased the specific surface area of the ion-exchange resins. This not only improved the drug loading of the resin, but also maximized the drug utilization rate.Table 1Drug loading and encapsulation rate of the optimized prescription of CS-rhIFNα-2b-CCPM (n=3)Batch123MeanSDRSD%*t*DL(μg·mg^−1^)15.019.3611.5411.972.8523.80*r*DL(μg·mg^−1^)13.558.4210.3310.772.5924.08*r*E (%)90.2789.9689.5189.910.380.43[^1]

In vitro release study {#S0006-S2003}
----------------------

As shown in [Figure 5C](#F0005){ref-type="fig"}, compared with the short serum half-life of the bulk drug (2--6 hrs),[@CIT0049] the potential of rhIFN-α-2b-CCPM to prolong the release of rhINF-α-2b was examined in an in vitro release study. The cumulative release rate was 88.78%. Therefore, rhIFN-α-2b-CCPM offered a slow release and was designated as an optimized nanoporous formulation. Next, to induce the sustained-release pattern, the nanopores were coated with chitosan by a self-assembly technique. As shown in [Figure 5C](#F0005){ref-type="fig"}, self-assembly did not affect the final release of the protein, but the initial release rate was significantly reduced compared to the self-made drug-loaded microspheres and stealth lipid-coated aquasomes bearing rhIFN-α-2b.[@CIT0049] Only 7.46% was released within 1 hr which effectively slowed down the initial release rate. The cumulative incomplete release may be due to the dynamic balance between drugs and exchangeable ions, and some drugs remained in the nanoporous microspheres and were not released completely. The fitting result from [Table 2](#T0002){ref-type="table"} showed that the linear relationship between the rhIFN α-2b-CCPM release curve in vitro and Viswanathan model was the best. The results also verified that rhIFNα-2b was bound to the nanoporous microspheres through ionic bonds and released through a particle diffusion mechanism. The in vitro release curve of CS-rhIFN-α-2b-CCPM can be fitted by a first-order release equation, indicating that the release mechanism of the nanoporous microspheres changed to membrane diffusion. The nanoporous microspheres displayed sustained-release characteristics.Table 2Results of the drug release behavior fitted by different kinetic models. (mean±SD, n=6)Kinetic modelrhIFNα-2b-CCPMCS-rhIFNα-2b-CCPMk±SDr^2^k±SDr^2^Zero-order model3.0206±0.290.72862.936±0.450.9462First-order model (film diffusion)0.0841±0.017 hr^−1^0.94060.0603^1^±0.0019 hr^−^0.9986Higuchi model (matrix diffusion)17.168±1.62 hr^−1/2^0.925317.023±2.38 hr^−1/2^0.9852Hixson and Crowell cube-root model0.0297±0.0098 hr^−3^0.88240.0717±0.013 hr^−3^0.9909Viswanathan0.264±0.0550.99180.198±0.0730.9759[^2]

SDS-PAGE {#S0006-S2004}
--------

The molecular weight of rhIFN α-2b is about 19 kDa. According to the literature,[@CIT0050] rhIFNα2b could be characterized by SDS--PAGE. [Figure 5D](#F0005){ref-type="fig"} shows that the positions of the bands for the different samples were identical, and no obvious aggregation and degradation bands were found. It showed that the purity of rhIFN α-2b was higher, and the stability of the protein prepared and released in this article was better. Sample 4 showed that rhIFN α-2b was hardly extracted from the nanoporous microspheres after 24 hrs of release in vitro, which is consistent with the results of the in vitro release. A very shallow band was observed in sample 5, indicating that a small amount of protein penetrated the ion-exchange column.

CD {#S0006-S2005}
--

RhIFNα-2b is a spherical structural protein composed of 5 alpha helices, with negative peaks at 208 nm and 222 nm. [Figure 5E](#F0005){ref-type="fig"} shows that the CD spectra of rhIFNα-2b-CCPM released in vitro was similar to the literature.[@CIT0036] Moreover, after the concentration of rhIFNα-2b was determined by the Coomassie brilliant blue method, there was no significant difference in the CD patterns between the same concentrations of the rhIFNα-2b releasing solution and the stock solution. It can be preliminarily concluded that the secondary structure of rhIFNα-2b did not change significantly after dynamic loading and in vitro release.

Relative biological activity at the cellular level in vitro {#S0006-S2006}
-----------------------------------------------------------

[Figure 5F](#F0005){ref-type="fig"} and [G](#F0005){ref-type="fig"} showed that in the range of 5--50 g/ml, the IR of rhIFNα-2b on A549 cells was dose-dependent, and increased with an increase in drug concentration, which had no difference with previous research papers.[@CIT0051] The results indicated that both the stock solution and releasing solution of rhIFNα-2b had an inhibitory effect on A549 proliferation in vitro for 72 hrs. In addition, at the same mass concentration, the relative biological activity of the releasing solution exceeded 91.98%, which indicated preliminarily that the CS-rhIFNα-2b--CCPM still maintained high biological activity against lung cancer cells after release for 24 hrs. The IC50 of rhIFNα-2b-CCPM was 18.915 μg/mL.

In vivo analytical methodology {#S0006-S2007}
------------------------------

A linear correlation (*r*=0.9995) was obtained between concentration and optical density of the rhIFNα-2b standard, and all plasma and tissue samples were between the range 7.5--240 pg/mL. The minimum detectable dose of rhIFNα-2b is 1.0 pg/mL. The maximum variation coefficient between the plates was 13.18%. From the literature,[@CIT0052] it was decided to collect the data for 3 separate experiments. According to the FDA guidelines, the mean value should be within 15% of the nominal value. The average recovery (%) of interferon in plasma and tissue samples is shown in [Table 3](#T0003){ref-type="table"}. All the %RSD were \<15%, suggesting that this method was accurate and reliable.Table 3Results of the recovery test (n=3)TissuesC (pg/mL)Recovery (%)Mean±SD（%）RSD (%)123Plasma1598.4182.7589.7190.29±6.418.696087.6893.3296.5492.51±3.664.8524097.5189.3193.293.34±3.354.39Liver1596.6785.1777.6586.50±7.8211.076087.3993.7187.4289.51±2.974.0724095.6596.2889.1693.70±3.224.21Lung1589.6897.3285.5490.85±4.886.586094.4185.7594.7191.62±4.155.5524087.5193.3198.293.01±4.375.75Kidney1586.0985.0299.0190.04±6.368.656093.879.6287.1186.84±5.798.1724095.3988.4490.291.34±2.953.96Heart1595.2381.1586.3487.57±5.818.136077.3294.1291.3387.59±7.3510.2824090.8785.7783.6186.75±3.044.30Spleen1585.6889.1593.789.51±3.284.496090.3284.3298.5491.06±5.837.8424086.5490.2297.4391.40±4.526.06Brain1598.2895.5484.1192.64±6.148.116091.9994.1685.0190.39±3.905.2924085.0889.9994.3489.80±3.785.16

In vivo pharmacokinetic parameters {#S0006-S2008}
----------------------------------

[Table 4](#T0004){ref-type="table"} and [Figure 6](#F0006){ref-type="fig"} show that rhIFNα-2b can be detected in blood from 5 min to 6 hrs after tail vein injection of the rhIFNα-2b solution. Over time, the rhIFNα-2b concentration in blood gradually decreased. After 6 hrs, the concentration of rhIFNα-2b was lower than the quantitative limit (7.5 pg/mL). After tail vein injection in mice, the pharmacokinetic parameters of the rhIFNα-2b solution and rhIFNα-2b nanoporous microspheres were different in vivo. After 1 h, the plasma drug concentration of the rhIFNα-2b nanoporous microspheres was significantly higher than that in the stock solution, and *T~max~, t~1/2~* and the mean residence time (MRT) were longer than those in the stock solution. rhIFNα-2b in the nanoporous microspheres can still be detected at 48 hrs after intravenous injection. It is shown that the nanoporous microsphere group had an obvious sustained-release effect. In summary, these findings were in accordance with the literature.[@CIT0053] The *AUC*~0-∞~ of rhIFNα-2b in the nanoporous microsphere group was lower than that in the solution group, which could be due to passive targeting of the nanoporous microspheres to the lung tissue after intravenous injection.Table 4Pharmacokinetic parameters in mice plasma (mean±SD, n=3)ParameterrhIFNα-2bCS-rhIFNα-2b-CCPM*T~max~* (h)0.08±0.021.5±0.03*C~max~* (pg·mL^−1^)3797±785846±222*MRT~0-∞~* (h)0.8±0.212.0±2.2*t~1/2~* (h)0.8±0.29.0±1.5*AUC~0-∞~* (pg·L^−1^·h)2488±11322159±747Relative bioavailability (F%)/86.8±6.6[^3] Figure 6Drug concentration--time data following i.v. administration of the rhIFNα-2b solution and nanoporous microspheres in mice (n=3).**Abbreviation:** CS-rhIFNα-2b-CMCS-MS, chitosan rhIFNα-2b carboxymethyl chitosan nanoporous microspheres.

Tissue distribution {#S0006-S2009}
-------------------

As can be seen from [Figure 7A](#F0007){ref-type="fig"} and [B](#F0007){ref-type="fig"}, the rhIFNα-2b solution was mainly distributed in the kidney and lung tissues, suggesting that it may have a good effect on renal and pulmonary tumors. After intravenous injection, the distribution of the nanoporous microspheres in the lung (anticipated target site) significantly increased, which was different from the literature,[@CIT0054] where local retention time was prolonged after the administration of the drug-loaded liposomes. The drugs in the nanoporous microsphere group can still be detected in the tissues at 24 hrs, equivalent to the drugs in the stock solution at 6 hrs, indicating that the nanoporous microspheres had a certain sustained-release effect in vivo.Figure 7Tissue distribution diagram after tail vein injection (ng·g^−1^) (n=3). (**A**) histogram of drug concentration in each tissue after 0.5, 1, 4, and 6 hrs after rhIFNα-2b stock solution injection into the tail vein of mice. (**B**) Histogram of drug concentration in various tissues after the injection of rhIFNα-2b nanoporous microspheres into the tail vein of mice after 1, 4, 6, and 24 hrs.

As can be seen from [Table 5](#T0005){ref-type="table"}, *C~i~* of the nanoporous microsphere group was 1.85 times that of the solution group, and CS-rhIFNα-2b-CCPM had an obvious lung-targeting effect.Table 5Target index in mice tissues (mean ± SD, n=3)Tissues*Ci* (pg/mL)*Ce*SolutionNanoporous microspheresLung283.36±32.89522.98±43.931.85±0.65Kidney582.71±67.56382.05±25.370.66±0.11Liver71.59±9.9780.63±17.661.13±0.38Heart142.88±23.35142.79±13.281.00±0.14Spleen77.29±8.5968.14±9.250.88±0.21Brain20.72±5.9215.25±4.270.73±0.21

Pharmacodynamic evaluation {#S0006-S2010}
--------------------------

As shown in [Figure 8A](#F0008){ref-type="fig"}, the growth of tumors significantly slowed down for the stock solution group and the microsphere group compared with the control group. At the end of treatment, the tumor volume of the control group was 1,020.35 mm^3^, and the tumor weight was 1.37±0.23 g. The tumor volume of the stock solution group was 780.94 mm^3^ and the tumor weight was 1.05±0.15 g. The tumor volume of the microsphere group was 729.17 mm^3^, and the tumor weight was 0.97±0.17 g. Tumor inhibition efficiencies of the stock solution group and the microsphere group were 23.4% and 29.2%, respectively. It can be concluded that the tumor volume and weight of the stock solution group and the microsphere group were significantly reduced compared with the control group. Furthermore, the microsphere group showed a better antitumor effect.Figure 8The evaluation of the antitumor effect (n=5). (**A**) The appearance of the tumors. (**B**) Histopathology slice of tumor (i: the control group; ii: the stock solution group; and iii: the microsphere group).**Abbreviation:** CS-rhIFNα-2b-CCPM, chitosan rhIFNα-2b carboxymethyl chitosan nanoporous microspheres.

It can be seen from [Figure 8Bi](#F0008){ref-type="fig"} that the tumor cells proliferate actively, with a diffuse distribution, tight arrangement, large cell volume, small nucleus, and dark blue chromatin. Some tumor cells were irregular in shape and size, with pathological mitosis, but there were no typical apoptotic cells. It can be seen from [Figure 8Bii](#F0008){ref-type="fig"} that there were obvious apoptotic cells in the tumor cells (the nucleus became smaller or almost disappeared). The uniformity of cell arrangement and distribution was worse, the morphological differentiation intensified, the tumor cell density decreased, the nuclear fragmentation increased, and there were some scattered empty bubbles. Similarly, it can be seen from [Figure 8Biii](#F0008){ref-type="fig"} that there were more apoptotic tumor cells (the nucleus became smaller or almost disappeared) while the number of active proliferating cancer cells reduced. Thus, apoptotic tumor cells were not evenly and uniformly distributed with intensified morphological differentiation, nuclear fragmentation and significantly increased scattered vacuoles. The results showed that the microsphere group (CS-rhIFNα-2b-CCPM) had a stronger antitumor effect.

Conclusion {#S0007}
==========

In view of the large molecular weight and poor physical and chemical stability of protein macromolecules, CS-rhIFNα-2b-CCPM was prepared for the first time to achieve a slow drug release in the lungs and enhance the specificity of pharmacological activity. This method has high encapsulation efficiency and high drug activity retention rate. CS-rhIFNα-2b-CCPM had an obvious sustained-release effect and a good targeting ability in vitro and in vivo. The in vitro cell experiments and anti-tumor effects in vivo proved that the prepared microspheres have a better antitumor effect, providing a new direction to study protein-based drug sustained-release preparations.
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[^1]: **Abbreviation:** CS-rhIFNα-2b-CCPM, chitosan rhIFNα-2b carboxymethyl chitosan nanoporous microspheres.

[^2]: **Abbreviations:** rhIFNα-2b-CCPM, rhIFNα-2b carboxymethyl chitosan nano-porous microspheres; CS-rhIFNα-2b-CCPM, chitosan rhIFNα-2b carboxymethyl chitosan nanoporous microspheres.

[^3]: **Abbreviations:** rhIFNα-2b-CCPM, rhIFNα-2b carboxymethyl chitosan nanoporous microspheres; CS-rhIFNα-2b-CCPM, chitosan rhIFNα-2b carboxymethyl chitosan nanoporous microspheres.
